Gefitinib ('Iressa', ZD1839) given in the 'Iressa' Expanded Access Programme in patients with non-small-cell lung cancer

被引：0
|
作者：
Chioni, A
Barbieri, F
Baldini, E
Orlandini, C
Ricci, S
Conte, PF
机构：
[1] Ciari Univ Hosp, Pisa, Italy
[2] Policlin Univ Hosp, Pisa, Italy
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S26 / S27
页数：2
相关论文
共 50 条
  • [41] Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
    H S Parra
    R Cavina
    F Latteri
    P A Zucali
    E Campagnoli
    E Morenghi
    G C Grimaldi
    M Roncalli
    A Santoro
    British Journal of Cancer, 2004, 91 : 208 - 212
  • [42] Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
    Parra, HS
    Cavina, R
    Latteri, F
    Zucali, PA
    Campagnoli, E
    Morenghi, E
    Grimaldi, GC
    Roncalli, M
    Santoro, A
    BRITISH JOURNAL OF CANCER, 2004, 91 (02) : 208 - 212
  • [43] Gefitinib ('Iressa', ZD1839) as third-line therapy for a patient with symptomatic brain metastases from non-small-cell lung cancer
    Azémar, M
    Stoll, C
    Unger, C
    BRITISH JOURNAL OF CANCER, 2003, 89 : S25 - S25
  • [44] Lessons from the ‘Iressa’ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations
    R Stahel
    A Rossi
    L Petruzelka
    P Kosimidis
    F de Braud
    M M Bernardo
    P-J Souquet
    H Soto Parra
    C Gridelli
    British Journal of Cancer, 2003, 89 : S19 - S23
  • [45] Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?
    Fujiwara, K
    Kiura, K
    Gemba, K
    Ogata, Y
    Hotta, K
    Kishino, D
    Tabata, M
    Ueoka, H
    Tanimoto, M
    ANTICANCER RESEARCH, 2005, 25 (1B) : 547 - 549
  • [46] Gefitinib ('Iressa', ZD1839), an option for patients with recurrent non-small-cell lung cancer who have failed chemotherapy: a case series report of 92 patients
    Haringhuizen, A
    Vaessen, HFR
    Baas, P
    van Zandwijk, N
    BRITISH JOURNAL OF CANCER, 2003, 89 : S29 - S29
  • [47] Efficacy, tolerability and improvement of symptoms in heavily pretreated patients with locally advanced or metastatic non-small-cell lung cancer treated with gefitinib ('Iressa', ZD1839)
    Petersen, V
    Grau, P
    Schneller, F
    Peschel, C
    BRITISH JOURNAL OF CANCER, 2003, 89 : S32 - S32
  • [48] Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme
    Xin-Lin Mu
    Long-Yun Li
    Xiao-Tong Zhang
    Shu-Lan Wang
    Meng-Zhao Wang
    BMC Cancer, 4
  • [49] Clinically meaningful response to the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
    Gelibter, A
    Ceribelli, A
    Milella, M
    Mottolese, M
    Vocaturo, A
    Cognetti, F
    BRITISH JOURNAL OF CANCER, 2003, 89 : S28 - S28
  • [50] Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme
    Mu, XL
    Li, LY
    Zhang, XT
    Wang, SL
    Wang, MZ
    BMC CANCER, 2004, 4 (1)
12345